Clinically, CDK4/6 inhibitors are the preferred systemic therapy for the treatment of patients with metastatic ER+ breast cancer who have become resistant to endocrine therapies; including through acquisition of ESR1 mutations (28). This evidence concerns the gene CDK4 and breast carcinoma.